PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28240376-14	2017	Assessment of TNF-alpha in response to combination treatment with enzalutamide and AEG40995 reveals increased mRNA expression and autocrine protein secretion.	enzalutamide	66-78	tumor necrosis factor	Homo sapiens	14-23	
28240376-16	2017	CONCLUSIONS: These findings suggest that IAP antagonists can increase sensitivity and amplify the caspase-mediated apoptotic response to enzalutamide through TNF-alpha signaling mechanisms.	enzalutamide	137-149	tumor necrosis factor	Homo sapiens	158-167	
26327448-8	2015	A soluble TNF receptor (etanercept) blocked enzalutamide-induced CCL2 protein secretion and mRNA, implying dependence on secreted TNF.	enzalutamide	44-56	tumor necrosis factor	Homo sapiens	130-133	
26327448-0	2015	TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures.	enzalutamide	26-38	tumor necrosis factor	Homo sapiens	0-3	
26327448-5	2015	We found that androgen withdrawal or enzalutamide induced TNF mRNA and protein secretion in castration resistant prostate cancer (C4-2) cells, but not in macrophage-like (THP1) or myofibroblast-like (WPMY1) cells.	enzalutamide	37-49	tumor necrosis factor	Homo sapiens	58-61	
26327448-8	2015	A soluble TNF receptor (etanercept) blocked enzalutamide-induced CCL2 protein secretion and mRNA, implying dependence on secreted TNF.	enzalutamide	44-56	tumor necrosis factor	Homo sapiens	10-13